CoChat

Advances in the development of new biomarkers for Alzheimer’s disease

Open access

The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a complex, heterogeneous, progressive disease and is the most common type of neurodegenerative dementia. The prevalence of AD is expected to increase as the population ages, placing an additional burden on national healthcare systems. There is a large need for new diagnostic tests that can detect AD at an early stage with high specificity at relatively low cost. The development of modern analytical diagnostic tools has made it possible to determine several biomarkers of AD with high specificity, including pathogenic proteins, markers of synaptic dysfunction, and markers of inflammation in the blood. There is a considerable potential in using microRNA (miRNA) as markers of AD, and diagnostic studies based on miRNA panels suggest that AD could potentially be determined with high accuracy for individual patients. Studies of the retina with improved methods of visualization of the fundus are also showing promising results for the potential diagnosis of the disease. This review focuses on the recent developments of blood, plasma, and ocular biomarkers for the diagnosis of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40035-022-00296-z

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Classification of AD biomarkers. AD pathogenic proteins include the markers of the "amyloid theory", amyloid-beta (Aβ)40 and Aβ42, as well as markers of AD-related metabolic disorders, P-Tau (phosphorylated) and T-Tau (total). Biomarkers obtained by lumbar puncture are cerebrospinal fluid (CSF) biomarkers, CSF Aβ1-42, CSF P-Tau, CSF T-Tau, and Neurogranin. Neurodegeneration markers include neurogranin and neurofilament light (NFL). The markers of inflammation include IL-1β and two soluble receptors sIL-1R1 and sIL-1R3, IL-8, SDF-1, intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion protein 1 (VCAM-1), progranulin, IL-33, and soluble interleukin 1 receptor-like (sST2). Many miRNAs are either up-regulated or down-regulated in studies on AD. The retina of the eye, as well as blood and plasma are being analyzed by a range of tools including single-molecular mass analysis (SIMOA), immunoprecipitation-mass spectrometry (IP-MS), immunomagnetic recovery (IMR), enzyme-linked immunosorbent assay (ELISA), and electrochemiluminescence immunoassays (ECL). Quantitative reverse transcription polymerase chain reaction (RT-qPCR) is used to identify miRNAs. The study of retinal degenerative changes, including ganglion cells and internal plexiform layers (GCIPL) and retinal nerve fiber layer (RNFL; p indicates peripapillary), is performed by optical coherence tomography (OCT) and spectral domain optical coherence tomography (SD-OCT)
Fig. 1 Classification of AD biomarkers. AD pathogenic proteins include the markers of the "amyloid theory", amyloid-beta (Aβ)40 and Aβ42, as well as markers of AD-related metabolic disorders, P-Tau (phosphorylated) and T-Tau (total). Biomarkers obtained by lumbar puncture are cerebrospinal fluid (CSF) biomarkers, CSF Aβ1-42, CSF P-Tau, CSF T-Tau, and Neurogranin. Neurodegeneration markers include neurogranin and neurofilament light (NFL). The markers of inflammation include IL-1β and two soluble receptors sIL-1R1 and sIL-1R3, IL-8, SDF-1, intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion protein 1 (VCAM-1), progranulin, IL-33, and soluble interleukin 1 receptor-like (sST2). Many miRNAs are either up-regulated or down-regulated in studies on AD. The retina of the eye, as well as blood and plasma are being analyzed by a range of tools including single-molecular mass analysis (SIMOA), immunoprecipitation-mass spectrometry (IP-MS), immunomagnetic recovery (IMR), enzyme-linked immunosorbent assay (ELISA), and electrochemiluminescence immunoassays (ECL). Quantitative reverse transcription polymerase chain reaction (RT-qPCR) is used to identify miRNAs. The study of retinal degenerative changes, including ganglion cells and internal plexiform layers (GCIPL) and retinal nerve fiber layer (RNFL; p indicates peripapillary), is performed by optical coherence tomography (OCT) and spectral domain optical coherence tomography (SD-OCT)CC BY · PubMed Central
Fig. 2 The effect of miRNAs on the pathology of AD. This image visualizes the effect of dysregulated miRNAs on neuronal degeneration. MiRNAs have an effect on the disruption of the cell cycle, regulation of Aβ metabolism, regulation of Tau-protein metabolism, and neuroinflammation
Fig. 2 The effect of miRNAs on the pathology of AD. This image visualizes the effect of dysregulated miRNAs on neuronal degeneration. MiRNAs have an effect on the disruption of the cell cycle, regulation of Aβ metabolism, regulation of Tau-protein metabolism, and neuroinflammationCC BY · PubMed Central
Fig. 3 Association of AD pathways with miRNAs with potential for diagnostic applications. As one of the key pathological pathways of AD development, Aβ has effects on the development of mitochondrial dysfunction, oxidative stress, and induction of the calcium signaling pathway. The calcium signaling pathway affects the development of apoptosis via lipid oxidation, protein oxidation, and DNA damage, leading to cell death. One of the mechanisms of neuronal damage is represented by hyperphosphorylated Tau protein, which causes neurofibrillary degeneration. The image also shows the effect of inflammatory factors on neuronal damage. TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; IKK, IκB kinase; PKR, protein kinase R; JNK, c-Jun N-terminal kinase; RAGE, receptor for advanced glycation endproducts; MEK, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IL, interleukin; mTOR, mechanistic target of rapamycin; VDCC, voltage-dependent calcium channel; Cdk5, cyclin dependent kinase 5; PP2B, protein phosphatase-2B; GSK3B, glycogen synthase kinase 3 beta; NMDAR, N-methyl-D-aspartate receptor; NOS, nitric oxide synthase; RyR, ryanodine receptors; PSEN, presenilin; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; FADD, Fas-associated protein with death domain; BID, BH3 interacting-domain death agonist; CytC, cytochrome complex; APP, amyloid precursor protein; APP-BP1, amyloid precursor protein-binding protein 1; BACE1, beta-site APP cleaving enzyme 1; Cx proteins I-V, electron transport chain enzymes (complexes I-IV) and the ATP synthase (complex V); ABAD, amyloid beta-binding alcohol dehydrogenase; CypD, mitochondrial peptidyl-prolyl cis–trans isomerase D
Fig. 3 Association of AD pathways with miRNAs with potential for diagnostic applications. As one of the key pathological pathways of AD development, Aβ has effects on the development of mitochondrial dysfunction, oxidative stress, and induction of the calcium signaling pathway. The calcium signaling pathway affects the development of apoptosis via lipid oxidation, protein oxidation, and DNA damage, leading to cell death. One of the mechanisms of neuronal damage is represented by hyperphosphorylated Tau protein, which causes neurofibrillary degeneration. The image also shows the effect of inflammatory factors on neuronal damage. TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; IKK, IκB kinase; PKR, protein kinase R; JNK, c-Jun N-terminal kinase; RAGE, receptor for advanced glycation endproducts; MEK, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinases; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; IL, interleukin; mTOR, mechanistic target of rapamycin; VDCC, voltage-dependent calcium channel; Cdk5, cyclin dependent kinase 5; PP2B, protein phosphatase-2B; GSK3B, glycogen synthase kinase 3 beta; NMDAR, N-methyl-D-aspartate receptor; NOS, nitric oxide synthase; RyR, ryanodine receptors; PSEN, presenilin; SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; FADD, Fas-associated protein with death domain; BID, BH3 interacting-domain death agonist; CytC, cytochrome complex; APP, amyloid precursor protein; APP-BP1, amyloid precursor protein-binding protein 1; BACE1, beta-site APP cleaving enzyme 1; Cx proteins I-V, electron transport chain enzymes (complexes I-IV) and the ATP synthase (complex V); ABAD, amyloid beta-binding alcohol dehydrogenase; CypD, mitochondrial peptidyl-prolyl cis–trans isomerase DCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 238 references

Research works printed but not linked: 1

  1. Zeng Q, Zou L, Qian L, Zhou F, Nie H, Yu S, et al. Expression of microRNA-222 in serum of patients with Alzheimer’s disease. Mol Med Rep. 2017;16(4):5575–9. · DOI

Cited by

See all 256

Metadata

Authors
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B.
Affiliations
  • Uppsala University (SE)
  • Sechenov University (RU)
Corresponding author
Schiöth, Helgi B.
Venue
Translational Neurodegeneration
Published
2022-04-21
Volume
11
Issue
1
Pages
25-25
ISSN
2047-9158 (ISSN-L)
OpenAlex
W4224247151
Cited by
241
References
238
Citations by year
2026: 34 · 2025: 65 · 2024: 85 · 2023: 47 · 2022: 10
FWCI
8.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • vetenskapsrådet
  • hjärnfonden
  • Uppsala University
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, biomarkers, early diagnosis, blood biomarkers, plasma biomarkers, ocular biomarkers, retina, microRNA, synaptic dysfunction, neuroinflammation, pathogenic proteins, diagnostic testing
MeSH terms
Alzheimer Disease, Humans, Retina, Biomarkers, Amyloid beta-Peptides, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advances in the development of new biomarkers for Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s40035-022-00296-z
The paper
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022). Advances in the development of new biomarkers for Alzheimer’s disease. Translational Neurodegeneration. https://doi.org/10.1186/s40035-022-00296-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.